In a financing deal, Cleveland Heart has received a $30 million investment that will aid efforts to bring its version of the total artificial heart to market.
That medical-device company is a joint venture between Charlotte-based Trans-World Medical Devices and Cleveland Clinic Foundation, the corporate venture arm of the Cleveland Clinic.
The financing investment was made by a Korean private-equity group, known as the Power Heart Consortium.
Further details of this financing agreement were not available. Cleveland Heart says the money will be used for further development and clinical trials for its artificial heart. The device will replace a patient’s heart prior to a transplant.
For further deal information visit Current Agreements (subscription required)
Read: more on financing deals in pharma, biotech, life science partnering deal news, insights and glossary
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Financing Scorecard – view top life science financing deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard– latest trends in big pharma deal making activity